Industry: Biotech Product: Tamara Application: Product launch uncertainties
A gene-therapy commercial launch — dossier assembly through first commercial shipment — was scheduled the orthodox way: eleven workstreams, each with a most-likely duration, chained through the network and read off the end as a clean January 2028 first shipment the company carried to its commercial leadership and its revenue model. The board's real question was never "is the date right?" — every experienced launch team knows a single-point date is optimistic. The question is the operational one: how much contingency do we commit to, and what level of confidence does it buy? A point estimate cannot answer that. A distribution can.
Rebuild the launch in Tamara, Vose Software's Monte Carlo project risk tool, with Beta-PERT durations and six discrete risk events, and the contingency ladder answers the board's question directly — each rung is the schedule reserve required to reach a given confidence level:
Against the 605-day deterministic plan, a P50 commitment needs +120 days (finishing day 725), an P80 commitment needs +190 days (day 795 — roughly 6.2 months of contingency), and a near-certain P95 needs +264 days (day 869). Read top-down, the ladder is a menu the board can choose from on the record: pick a confidence level, read the committed reserve, and the rolling-promise cycle is over before it starts. The January 2028 plan, by contrast, carries just a 4% chance of being met — it is the bottom of a ladder, not a rung anyone should stand on.
Every day to launch carries program-team burn, idle CMO reservation and the carrying cost of deferred revenue, so the schedule reserve the board picks is also a budget reserve. Plotting each simulated run in the finish-date / total-cost plane shows the two are one risk on two axes:
The cloud runs diagonally — late runs are over-budget runs — and in 18% of simulations the launch finishes both late AND over the $66M budget, in the dangerous upper-right quadrant. Pricing three mitigations together (pre-submission scientific-advice meetings with FDA and EMA that shorten response cycles, an at-risk CMO scale-up started before approval with a confirmation run, and an early payer dossier with dual cold-chain lanes) cuts the P80 finish by 49 days (795 to 746 days) and, because schedule drives cost, takes the overrun probability from 18% to 7% — the $2.5M package pays for itself in avoided carrying cost. Choosing a rung on the ladder and pricing this package are the same decision viewed twice.
To know which reserve to attack first, Tamara ranks each workstream by its cruciality — the rank-correlation between its duration and the launch finish:
The tech-transfer rework loop leads (cruciality 0.52), followed by process validation and release (0.40) and CMO tech transfer and scale-up (0.38). This is the action list, and it is not where leadership expected it: the launch date is governed more by the manufacturing-readiness chain at the contract manufacturer than by any single regulatory review. Duration certainty on tech transfer and validation buys more end-date — and shrinks the ladder more — than anything else.
Six events were modelled as Bernoulli risks — each may or may not occur, but if it does it adds delay and cost. Ranking them by expected schedule impact (probability x delay) gives a clean Pareto:
Four of the six events carry roughly 80% of the expected discrete-event delay — an EU / Japan procedural delay (6.0 weeks expected), an FDA complete-response / questions cycle (5.0), a CMO tech-transfer failure (4.2) and a reimbursement / payer holdout (3.3). Regulatory cycles and the CMO failure together dominate, which tells leadership exactly where the response budget belongs — and explains the height of the upper rungs on the ladder.
Collapsing the schedule onto its shipment-date axis shows the shape behind every rung of the ladder:
The deterministic January 2028 plan sits at the extreme left edge of the body — a near-best case, not a central estimate — with the bulk of outcomes between P50 May 2028 and P90 September 2028 and a long right tail. The mean simulated finish is 730 days against the 605-day plan. The histogram is the ladder's raw material: every percentile the board commits against is read straight off this distribution.
A product launch is not a date; it is a distribution the board commits against one confidence level at a time. Tamara is what turns "when do we ship?" into a ladder of fundable choices the commercial team, the board and the supply chain can all sign.